FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesLeading Up
Topics: Communication, Management, Personal Development, Team Building
Abstract
Members
Understanding Blockchain and AI in the Clinical Supply Chain
Topics: Conference, Supply Chain
Video
Members
Industry Evolution – A Vision of the Clinical Supply Chain in the Next Decade
Topic: Supply Chain
White Paper
Free
